Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

An overview of IL-7 biology and its use in immunotherapy.

ElKassar N, Gress RE.

J Immunotoxicol. 2010 Mar;7(1):1-7. doi: 10.3109/15476910903453296.

2.
3.

Ongoing Dll4-Notch signaling is required for T-cell homeostasis in the adult thymus.

Billiard F, Kirshner JR, Tait M, Danave A, Taheri S, Zhang W, Waite JC, Olson K, Chen G, Coetzee S, Hylton D, Murphy AJ, Yancopoulos GD, Thurston G, Skokos D.

Eur J Immunol. 2011 Aug;41(8):2207-16. doi: 10.1002/eji.201041343. Epub 2011 Jul 4.

4.

Interleukin-7 supports survival of T-cell receptor-β-expressing CD4(-) CD8(-) double-negative thymocytes.

Xiong J, Parker BL, Dalheimer SL, Yankee TM.

Immunology. 2013 Apr;138(4):382-91. doi: 10.1111/imm.12050.

5.
6.

Effect of IL-7 Therapy on Naive and Memory T Cell Homeostasis in Aged Rhesus Macaques.

Okoye AA, Rohankhedkar M, Konfe AL, Abana CO, Reyes MD, Clock JA, Duell DM, Sylwester AW, Sammader P, Legasse AW, Park BS, Axthelm MK, Nikolich-Žugich J, Picker LJ.

J Immunol. 2015 Nov 1;195(9):4292-305. doi: 10.4049/jimmunol.1500609. Epub 2015 Sep 28.

8.

Microparticle delivery of Interleukin-7 to boost T-cell proliferation and survival.

Wang NX, Bazdar DA, Sieg SF, von Recum HA.

Biotechnol Bioeng. 2012 Jul;109(7):1835-43. doi: 10.1002/bit.24431. Epub 2012 Jan 27.

PMID:
22275058
9.

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.

J Exp Med. 2008 Jul 7;205(7):1701-14. doi: 10.1084/jem.20071681. Epub 2008 Jun 23.

10.

IL-7 Abrogates the Immunosuppressive Function of Human Double-Negative T Cells by Activating Akt/mTOR Signaling.

Allgäuer A, Schreiner E, Ferrazzi F, Ekici AB, Gerbitz A, Mackensen A, Völkl S.

J Immunol. 2015 Oct 1;195(7):3139-48. doi: 10.4049/jimmunol.1501389. Epub 2015 Aug 31.

11.
15.

Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.

Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, Setti M, Accolla RS, Puppo F, Indiveri F.

Hum Immunol. 2004 Feb;65(2):142-56.

PMID:
14969769
17.

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.

Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Klebanoff CA, Tagaya Y, Restifo NP.

J Immunol. 2006 May 1;176(9):5255-66. Erratum in: J Immunol. 2006 Jun 15;176(12):7788. Heinrichs, Christian [corrected to Hinrichs, Christian S].

18.

Interleukin-7 treatment promotes the differentiation pathway of T-cell-receptor-alpha beta cells selectively to the CD8+ cell lineage.

Varas A, Vicente A, Jiménez E, Alonso L, Moreno J, Muñoz JJ, Zapata AG.

Immunology. 1997 Dec;92(4):457-64.

19.

Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.

Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M.

Blood. 2006 Dec 15;108(13):4260-7. Epub 2006 Aug 17.

20.

Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis.

Jaleco S, Swainson L, Dardalhon V, Burjanadze M, Kinet S, Taylor N.

J Immunol. 2003 Jul 1;171(1):61-8.

Supplemental Content

Support Center